OBJECTIVE To analyze the effects of pioglitazone in patients with good adherence as well as intention-to-treat effects of pioglitazone in patients with prediabetes in the IRIS trial.
D
iabetes is an important risk factor for stroke. 1, 2 Adverse cardiovascular effects of diabetes are associated with insulin resistance, which is present in 50% of patients with stroke or transient ischemic attack who do not have diabetes.
3 Insulin resistance is associated with increased blood pressure, serum low-density lipoprotein cholesterol, triglycerides, coagulation, inflammatory markers, platelet reactivity, reduced high-density lipoprotein cholesterol, and vascular reactivity. [4] [5] [6] Pioglitazone also has antiatherosclerotic effects 7, 8 ;i treduces insulin resistance by activating peroxisome proliferatoractivated receptors-γ and also causes partial minor activation of peroxisome proliferator-activated receptors-α, 9 which promotes uptake, use, and catabolism of fatty acids.
10
In the Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive) study, fatal/nonfatal stroke was reduced by 47%. 11 In the Insulin Resistance Intervention After Stroke (IRIS) trial, pioglitazone reduced new-onset diabetes by half and reduced stroke or myocardial infarction (MI) by 24%.
12
In a meta-analysis of studies in patients with stroke and insulin resistance, prediabetes, and diabetes mellitus, pioglitazone was associated with a 42% lower risk of recurrent stroke. 13 Adverse events that were more common in individuals using pioglitazone in the IRIS trial included weight gain, edema, and bone fractures. Inclusion in the IRIS trial was based on the homeostatic model assessment of insulin resistance (HOMA-IR) score, a measure of insulin resistance (fasting blood glucose in milligrams per deciliter × fasting insulin level in milliunits per liter/ 405). Homeostatic model assessment of insulin resistance is not commonly measured, so the IRIS results may be perceived as having limited application in clinical practice.
Therefore, to translate the IRIS trial results to real-world practice, we present analyses for patients with prediabetes, as defined by the American Diabetes Association. Results for participants with prediabetes by the more conservative definitions of the World Health Organization (WHO) are presented in eTable 3, eTable 4, and the eFigure in Supplement 1. Because we wished to assess the potential benefit of pioglitazone in real-world practice, we emphasized the results in participants who were adherent to therapy, with adherence defined as taking 80% or more of the protocol dose over the duration of the study.
Methods

Study Design
In the IRIS trial, 12 insulin resistance was defined as a HOMA-IR score higher than 3. Participants without diabetes with ischemic stroke or transient ischemic attack who had insulin resistance were randomized 1:1 to placebo or pioglitazone. The dose of study drug was titrated up from 15 mg of pioglitazone per day or matching placebo to 45 mg per day over 3 months, and participants continued receiving the highest dose tolerated. The present study is a post hoc, exploratory subgroup analysis. Fasting glucose and hemoglobin A 1c (HbA 1c ), used to define prediabetes, and adherence of 80% or higher, stipulated in the protocol as defining good adherence, were prespecified subgroups in the analysis plan. The statistical analysis plan is available in Supplement 2.
Trial Conduct and Ethics
The study was approved by the local ethics committee at each site. Participants gave written consent. The trial was monitored by an independent data and safety monitoring board appointed by the National Institute of Neurological Disorders and Stroke, which funded the study.
Patient Population
Of 3876 participants in the IRIS trial, we analyzed results of pioglitazone therapy in patients with prediabetes based on the American Diabetes Association criteria. 14 Selection of participants is shown in Figure 1 . Good adherence was specified in the IRIS protocol as taking 80% or more of the protocol dose over the duration of the study as measured by pill counts on returned bottles. This is one of several common definitions of good adherence across trials.
17
The primary end point was recurrent fatal or nonfatal stroke, or MI. Secondary outcomes were recurrent stroke; acute coronary syndrome; the composite of stroke/MI/hospitalization for heart failure; and the progression to diabetes. In these analyses, we used updated criteria for stroke and MI. 18, 19 Preselected safety events (ie, bone fracture, heart failure, and cancer) were adjudicated by the members of independent committees in a blinded fashion.
Statistical Methods
Categorical variables were summarized as percentage, and differences between groups were compared by the χ 2 test. Continuous variables were summarized as mean (SD); differences between groups were analyzed by analysis of variance. Hazard analyses were completed by Cox regression. Relative risk reductions (RRRs) were calculated as percent reduction of events. Cumulative event-free rates were calculated by the Kaplan-Meier method. 20 A 2-sided P value less than .05 was regarded as significant. Statistical tests were performed using SPSS, version 25 (IBM Corporation) and SAS software, version 9.4 (SAS Institute Inc). As it is known that patients with good adherence tend to have better outcomes, 21 we compared participants with good adherence in both arms of the study.
Results
By the American Diabetes Association criteria, there were 2885 participants with prediabetes and 1410 with prediabetes by the more restrictive WHO criteria. Results presented here are for patients with prediabetes by the US criteria; Figure 1 (Table 1) . Fasting blood glucose level, systolic and diastolic blood pressure, triglyceride level, and high-density lipoprotein cholesterol level were all significantly better during treatment with pioglitazone (eTable 2 in Supplement 1). Reductions in outcomes and RRRs with pioglitazone were for stroke/MI, from 83 (10.2%) to 39 (6.1%), RRR = 40%; for stroke, 61 (7.5%) to 32 (5%), RRR = 33%; for acute coronary syndrome, 39 (4.8%) to 15 (2.3%), RRR = 52%; and for stroke/MI/hospitalization for heart failure, 84 (10.4%) to 42 (6.5%), RRR = 38%. New-onset diabetes was reduced by pioglitazone from 82 (10.1%) to 13 (2.0%), RRR = 80%. Hazard ratios with 95% CI and numbers needed to treat (NNT) for statistically significant differences are shown in Table 2 and time-to-event curves in Figure 2 .
Effects of pioglitazone were numerically greater among IRIS participants with prediabetes than in those without prediabetes; however, the differences were not significant (eTable 1 in Supplement 1). The results for patients with prediabetes by the WHO definition were similar to the results for prediabetes defined by US criteria but with the smaller sample size were not statistically significant except for new-onset diabetes (eTable 2, eTable 3, and eFigure in Supplement 1).
Intention-to-Treat Analyses
Among 2885 participants with prediabetes, 1456 (50.5%) were randomized to pioglitazone and 1429 (49.5%) to placebo. Baseline characteristics of the patients with prediabetes by randomized treatment group are shown in eTable 5 in Supplement 1. The mean (SD) age of patients was 64 (11) years, and 974 (66.9%) and 908 (63.5%) were men in the pioglitazone group and placebo group, respectively. Reductions in outcomes and RRRs with pioglitazone were for stroke/MI, from 179 (12.5%) to 130 (8.9%), RRR = 29%; for stroke, 135 (9.4%) to 100 (6.9%), RRR = 27%; for acute coronary syndrome, 84 (5.9%) to 62 (4.3%), RRR = 27%; and for stroke/MI/hospitalization for heart failure, 193 (13.5%) to 154 (10.6%), RRR = 22%. New-onset diabetes was reduced by pioglitazone from 142 (9.9%) to 69 (4.7%), RRR = 53%. Hazard ratios and 95% CI as well as NNT for statistically significant results are shown in Table 2 . For patients without prediabetes, effects of pioglitazone were attenuated but not statistically different compared with patients with prediabetes (eTable 1 in Supplement 1).
Adverse Outcomes
Among the participants with good adherence, serious bone fractures occurred in 23 patients (3.6%) in the pioglitazone group vs 23 patients (2.8%) in the placebo group. Weight gain of 10% or more occurred in 192 (29.8%) in the pioglitazone group vs 97 (12.0%) in the placebo group; edema occurred in 188 (29.2%) in the pioglitazone group vs 175 (21.6%) in the placebo group. There was a slight and nonsignificant reduction in all-cause mortality, cancer, and hospitalization with pioglitazone, and no significant increase in heart failure. Table 3 shows hazard ratio and 95% CI, and number needed to harm, for statistically significant differences. Adverse events for the ITT analysis followed the same pattern (eTable 5 in Supplement 1).
Discussion
Among IRIS study participants with prediabetes and good adherence, pioglitazone reduced stroke/MI by 40%, stroke by 33%, acute coronary syndrome by 52%, and new-onset diabetes by 80% over a median follow-up of 4.8 years. The effect sizes in the ITT analysis of those with prediabetes were smaller (29%, 27%, 27%, and 53%, respectively). These findings were observed despite a higher proportion of men and smokers, higher diastolic blood pressures, and lower high-density lipoprotein cholesterol levels among individuals with good adherence assigned to receive pioglitazone. These associations of pioglitazone in the cohort with good adherence were greater than the associations observed in the ITT cohort or in the full trial cohort probably because this was an analysis of participants with good adherence and also perhaps because participants with prediabetes had higher HbA 1c level and HOMA-IR scores than those without prediabetes. As shown in Figure 2 , the benefit of pioglitazone continued to increase over time, suggesting that even greater benefits might have been shown with longer follow-up. Some or much of this may have been due to prevention of diabetes over time. A 2018 study from the Swedish National Diabetes Register reported that in individuals with diabetes, the strongest predictor of cardiovascular adverse events was HbA 1c .
22
A question that arises from our findings is whether patients can be selected for pioglitazone therapy after stroke or transient ischemic attack based on prediabetes rather than the HOMA-IR test. It is not possible to provide a definitive answer to this question because all of the patients in our secondary analysis were enrolled in the study based on a HOMA-IR criterion. However, we believe such a strategy is reasonable (eg, 6.0%) to select patients with a very high probability of advanced insulin resistance. Participants with prediabetes had greater benefit from pioglitazone than those in the IRIS trial, although adherence was slightly less. In the IRIS trial, the percentage of participants with good adherence was 45.2% in the pioglitazone cohort vs 58.2% in the placebo cohort. In participants with prediabetes, 44.5% in the pioglitazone group had good adherence vs 57.3% in the placebo group. Notably, this is the first time, to our knowledge, that any glucose-lowering treatment has been demonstrated to reduce vascular events in a population with prediabetes. Prediabetes is a recognized risk factor for ischemic stroke, 24 especially for recurrent stroke. A 2018 study also found that subclinical cerebral infarcts were more than 60% more common in individuals with prediabetes than in those with euglycemia and that this relative increase was nearly as high as observed in those with overt diabetes. 25 Accordingly, our data support the notion of early treatment of prediabetes to improve clinical outcomes in those with established vascular disease. Although ITT analysis is usually regarded as de rigeur, there are good reasons to also perform analyses that show the po- tential of a treatment among persons able to take it. Hernán and Robins 26 discussed this issue, saying that ITT analysis may not be directly relevant for guiding decisions in clinical settings with different adherence patterns. Sheiner and Rubin 27 made the distinction between "use effectiveness" (the result of prescribing a medication) and "method effectiveness" (the result of taking a medication). They pointed out that for the purpose of treating individual patients, method effectiveness was a more useful pharmacologic characteristic. This may be particularly true for drugs, which, like pioglitazone, have adverse effects that limit adherence in some patients but not in others. For patients who can take pioglitazone, it appears to be very beneficial; some patients may not be able to take it if fluid retention is excessive. As seen in Table 3 , a common adverse effect of pioglitazone is edema, which accounts for much (but not all) of the weight gain. Although we did not observe an increase in heart failure with pioglitazone in the IRIS trial, there have been concerns about heart failure as an adverse effect of pioglitazone. There appear to be 2 mechanisms contributing to edema: salt and water retention due to effects on the renal tubular epithelial sodium channel and other effects in the collecting duct 28 and perhaps increased vascular permeability. 29 There are maneuvers that can be implemented to minimize the problem of fluid retention. The simplest would be to use a lower dose of pioglitazone. The usual doses of pioglitazone are 15 mg, 30 mg, or 45 mg daily, but a 2017 review indicated that 7.5 mg daily confers much of the benefit of pioglitazone with less weight gain and fluid retention.
30 Initiating the drug with dose titration, with a prescription that specifies repeats of the dose that did not cause a problem is 1 approach to mitigating the problem with fluid retention. Another is the use of amiloride, a specific antagonist of epithelial sodium channel. The centrality of the renal tubular epithelial sodium channel to salt and water retention and the importance of considering the use of amiloride, a seldom-used drug, were recently reviewed. 31 It seems likely that amiloride, a specific antagonist of epithelial sodium channel, 32 may be useful in counteracting the weight gain and fluid retention due to pioglitazone. 33 (Vigilance should be exercised with regard to hyperkalemia in patients with impaired renal function.) Amiloride was reported to be more efficacious than spironolactone in reducing fluid retention with pioglitazone.
33
From the perspective of the payer, with regard to direct cost of medication, what matters more is what happens when patients use a treatment since there are no medication costs for those who do not. Third-party payers who also cover the costs of costly complications such as stroke should also consider the cost of not taking medications. The economic benefits of pioglitazone with regard to prevention of MI/stroke (NNT, 24), stroke (NNT, 39), and diabetes (NNT, 12) may be offset somewhat by the cost of events such as fractures (number needed to harm, 125). Myocardial infarction and stroke are very costly, c Adjudicated episode of heart failure causing hospitalization or death.
d Adjudicated events that do not meet criteria for serious as defined above.
e Weight change of 10% of more from baseline at any time in trial. so the balance of NNTs for beneficial outcomes and numbers needed to harm for adverse outcomes would suggest cost utility for pioglitazone, but we have not yet conducted a costutility calculation. To achieve the greatest benefit of pioglitazone in prediabetes it would probably be better to use the US definition rather than the WHO definition.
Limitations
There are limitations to our analyses. All the participants in the IRIS trial had insulin resistance; these analyses pertain to the subgroup with prediabetes, who had significantly higher HOMA-IR scores. We cannot know the effectiveness of pioglitazone in patients with prediabetes and HOMA-IR scores less than or equal to 3, although this would be an infrequent scenario. Also, the diabetes end point was simply based on fasting glucose levels and patient reports. Hemoglobin A 1c testing was not performed after the baseline visit, and oral glucose tolerance testing was not part of the protocol. As such, our diagnostic rate for new-onset diabetes was likely reduced, although this should not have introduced a bias.
Conclusions
Pioglitazone appears to reduce the risk of recurrent stroke or MI, recurrent stroke, acute coronary syndrome, and diabetes in patients with insulin resistance and prior stroke/transient ischemic attack and prediabetes, particularly in individuals who adhere to therapy. These benefits appear to outweigh the risks of fracture and fluid retention. Funding/Support: The IRIS trial was supported by a grant (U01NS044876) from the National Institute of Neurological Disorders and Stroke. Takeda Pharmaceuticals International Inc donated pioglitazone and matching placebo for the trial and had the right to a delay of up to 6 weeks before submission of the paper for patent purposes.
Role of the Funder/Sponsor: Neither the funding agency nor Takeda had a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
14. American Diabetes Association. 17.6% 14.0% 0.064 HDL-C = high density lipoprotein cholesterol; LDL-C = low density lipoprotein cholesterol Conversion to SI units: multiply blood glucose x 0.0555; multiply total cholesterol, HDL-C and LDL-C x 0.0259; multiply triglycerides x 0.0113.
In 2010, the ADA revised the criteria for diabetes to include hemoglobin A1c > 6.5% (confirmed by repeat testing). To determine how the IRIS results would be affected by use of this revised definition, we will conduct a sensitivity analysis using the revised criteria. No other aspects of the IRIS DM outcome classification are affected.
